NCT02953106 (MAN06) is a Phase 4 clinical trial of Azelastine-Fluticasone Nasal in Asthma, Allergic, sponsored by University of Dundee.

Who is sponsoring NCT02953106?

NCT02953106 is sponsored by University of Dundee.

What drugs are being tested in NCT02953106?

Interventions in NCT02953106: Azelastine-Fluticasone Nasal, Placebos.

What condition does NCT02953106 study?

NCT02953106 studies Asthma, Allergic, Rhinitis,Allergic, Allergy.

Is NCT02953106 still recruiting?

NCT02953106 is currently terminated. Last updated 8 April 2019.

Last reviewed 2019-04-08 · How we verify

NCT02953106: MAN06

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

Terminated Phase 4 Last updated 8 April 2019

What this trial tests

Phase 4 trial testing Azelastine-Fluticasone Nasal in Asthma, Allergic in 7 participants. Terminated before completion.

Timeline

20 January 2017

Primary endpoint
10 September 2018

10 September 2018

Quick facts

Lead sponsor	University of Dundee
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	7
Start date	20 January 2017
Primary completion	10 September 2018
Estimated completion	10 September 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Azelastine-Fluticasone Nasal — full drug profile →
Placebos — full drug profile →

Conditions studied

Asthma, Allergic — all drugs for Asthma, Allergic →
Rhinitis,Allergic — all drugs for Rhinitis,Allergic →
Allergy — all drugs for Allergy →

Sponsor

University of Dundee

Who can join

18 and older, any sex, with Asthma, Allergic or Rhinitis,Allergic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single centre, double-blind, placebo controlled, adaptive design, cross-over trial. The primary objective is to assess the additive effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on airway hyperresponsiveness. This is in patients with persistent asthma and allergic rhinitis, receiving inhaled steroid.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma, Allergic

Currently open trials in the same condition.

NCT03455959 — Lung-Resident Memory Th2 Cells in Asthma · NA · active not recruiting

Other University of Dundee trials

Trials by the same sponsor.

NCT06435156 — Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes · Phase 2 · recruiting
NCT05582798 — Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function · Phase 4 · completed
NCT04419805 — Single Palatal Temporary Anchorage Device for Anterior Open Bite · NA · unknown
NCT03747107 — Pharmacist and Data Driven Quality Improvement in Primary Care · completed
NCT04817332 — STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02953106 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Dundee
Last refreshed: 8 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing